UNSPSC 51442438: Sodium iodide i-131

This classification denotes a sodium iodide radioactive with the molecular formula NAI, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29VCO8ACHH, more generally known as sodium iodide i-131. European Medicines Agency schedules sodium iodide i-131 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12294MIG. The term SODIUM IODIDE (131I) is an International Non-Proprietary Name or INN. As of Q4 2014, SODIUM IODIDE I-131 remains the US FDA Preferred Term for this commodity.

Sodium iodide i-131 bears US NLM identifiers UMLS ID C0304982 and NCI Concept Code C47725. SMILES: [Na+].[I-].

UNSPSC 51442438 Sodium iodide i-131 is a Commodity code with minimal recent state and local procurement activity aligned to its nominal scope. The recent opportunities tagged under this code show a mismatch: three of the four most recent solicitations address X-ray equipment, maintenance services, and radiologic systems—not radioactive isotopes or medical imaging radiopharmaceuticals. One opportunity from Pasco County, Florida (RFQ, due June 26, 2026) solicited copper sulfate crystals and liquid copper sulfate on an as-needed basis, which is similarly unrelated to the code's product definition. The code shows no recent direct demand from state or local governments for sodium iodide i-131 or equivalent radioisotopes used in diagnostic or therapeutic nuclear medicine.

Geographic activity in the tagged opportunities spans Florida (Escambia County Correction, Broward County Aviation Department, Pasco County) and Arizona (Maricopa County), but the misalignment between the code and the actual work solicited suggests these postings may reflect systematic tagging errors or platform categorization drift. When procurement does occur for radioisotopes like sodium iodide i-131 at the state and local level, it typically flows through specialized medical imaging departments at academic medical centers or large hospital systems rather than through general procurement channels. Firms pursuing this code should verify directly with target customers whether they maintain active demand for radiopharmaceutical products before investing in pursuit strategy.